We maintain our Buy rating, reflecting our continued confidence in Barco's positioning within its niche markets and the ongoing enhancements to its product lineup. However, after the company communicated more modest long-term growth and margin objectives at the CMD, we have reduced our forecasts and, as a result, lowered our target price to €16.0 (previously €17.5).
Arcadis: US peer Aecom sets a new standard for EBITDA margin potential. Belgian telecoms: Orange Belgium price increases from January. CFE: Keeps outlook, materially lower QoQ net debt. Flow Traders: Market volumes improve in October. IMCD: Awaiting a recovery. Kinepolis: Launches retail bond issuance for €100-150m. NEPI Rockcastle: Sound operational performance continues. Universal Music Group: EU to warn on Downtown deal
Fagron completes share buy-back program Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 14 November 2025 – 6PM CET Fagron completes share buy-back program In the period from 10 November 2025 through 14 November 2025, Fagron purchased 44,000 of its owns shares at an average price of €20.7208 per share corresponding to a total amount of €911,717.00. A total of 200,000 Fagron shares have been repurchased under the buy-back program at an average price of € 20.6805 per share, corresponding to a total amount of € 4,136,093.00. The share buy-back program was announced on ...
Voortgang aandeleninkoopprogramma Fagron Gereglementeerde informatie Nazareth (België)/Rotterdam (Nederland), 14 november 2025 – 18u CET Voortgang aandeleninkoopprogramma Fagron In de periode van 10 november 2025 tot en met 14 november 2025 heeft Fagron 44.000 eigen aandelen ingekocht voor een gemiddelde prijs van € 20,7208 per aandeel wat overeenkomt met een totaalbedrag van € 911.717,00. Het totaal van 200.000 Fagron aandelen is aangekocht tegen een gemiddelde koers van € 20,6805 per aandeel, wat overeenkomt met een totaalbedrag van € 4.136.093,00. Het aandeleninkoopprogramma was aan...
Aegon trading update for third quarter 2025 Schiphol, November 13, 2025 - Please click to access all 3Q 2025 trading update related documents. EUR 340 million operating capital generation (OCG) before holding funding and operating expensesCapital ratios of Aegon’s main units remain strong, above their respective operating levelsCash Capital at Holding at EUR 1.9 billion, reflecting the sale of 12.5 million shares in a.s.r. for EUR 700 million, the payment of the 2024 final dividend and the 2025 interim dividend, and 54% completion of the ongoing EUR 400 million share buyback programOn tr...
Two Directors at Crescent NV bought/sold 95,490,000 shares at between 0.007EUR and 0.007EUR. The significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over...
Fagron’s share buy-back program: Weekly update Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 7 November 2025 – 6PM CET Fagron’s share buy-back program: Weekly update In the period from 3 November 2025 through 7 November 2025, Fagron purchased 45,000 of its owns shares at an average price of €20.4413 per share corresponding to a total amount of €919,856.70. These purchases are part of the share buy-back program of up to 200,000 Fagron shares to fulfill Fagron’s obligations under its long-term incentive scheme, which was announced on 9 October 2025. The total numbe...
Voortgang aandeleninkoopprogramma Fagron Gereglementeerde informatie Nazareth (België)/Rotterdam (Nederland), 7 november 2025 – 18u CET Voortgang aandeleninkoopprogramma Fagron In de periode van 3 november 2025 tot en met 7 november 2025 heeft Fagron 45.000 eigen aandelen ingekocht voor een gemiddelde prijs van € 20.4413 per aandeel wat overeenkomt met een totaalbedrag van € 919.856,70. Deze aankopen zijn gedaan als onderdeel van het aandeleninkoopprogramma van maximaal 200.000 Fagron aandelen ter afdekking van Fagron’s verplichtingen uit hoofde van haar langetermijn variabele belonings...
Galapagos reported 9M25 results with a cash position of € 3,050m (YE24: € 3,317.8m) and an updated outlook, where it expects to end FY25 with € 2,975- € 3,025m in cash, and to incur costs of € 250-325m related to the winddown of the cell therapy business. Looking ahead, the company will focus its strategy on building a new pipeline through BD, and more information on BD strategy will be provided during this afternoon's conference call. € 37 TP and ACCUMULATE maintained.
Galapagos Reports Nine Months 2025 Financial Results and Provides Business Update Strategic review process concluded with intention to wind down cell therapy business, representing optimal capital allocation pathway to support a stronger and sustainable future for GalapagosContinued evolution of leadership team aligned with strategic directionRobust balance sheet with €3.05 billion in cash and financial investments as of September 30, 2025; year-end 2025 cash position expected at €2.975 billion to €3.025 billion Management to host a tomorrow, November 6, 2025, at 14:00 CET / 08:00 AM ET ...
Galapagos rapporteert financiële resultaten over de eerste negen maanden van 2025 en geeft bedrijfsupdate Strategisch evaluatieproces afgerond met de intentie om de celtherapieactiviteiten af te bouwen, wat de optimale kapitaalallocatie vertegenwoordigt ter ondersteuning van een sterkere en duurzame toekomst voor GalapagosVerdere ontwikkeling van het leiderschapsteam sluit aan bij de strategische richtingRobuuste balans met €3,05 miljard in geldmiddelen en financiële investeringen per 30 september 2025; verwachte kaspositie eind 2025 tussen €2,975 miljard en €3,025 miljardManagement organis...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.